Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Zanaboni

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Gynecologic Oncology|November 1, 1990
The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapyG Bolis, F Zanaboni, P Vanoli, et al.
Gynecologic Oncology|November 1, 1988
EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)G Bolis, C Bonazzi, F Landoni, et al.
Minerva Ginecologica|January 1, 1993
[Endometrial adenocarcinoma during the fertile age]M Franchi, P Tenti, F Ghezzi, et al.
Gynecologic Oncology|February 24, 2000
Clinical value of intraoperative gross examination in endometrial cancerM Franchi, F Ghezzi, M Melpignano, et al.
Journal of the National Cancer Institute|October 1, 1986
Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumorsP Allavena, F Zanaboni, S Rossini, et al.
The International Journal of Biological Markers|May 1, 1987
The biological tumor markers' myopia: a model with CA 125 and second-look in ovarian cancerF Zanaboni, G Accinelli, P Colombo, et al.
The International Journal of Biological Markers|January 1, 1991
Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEAF Boccardo, E Bombardieri, S Zanardi, et al.
Gynecologic Oncology|June 1, 1996
Octreotide in the management of bowel obstruction in terminal ovarian cancerG Mangili, M Franchi, A Mariani, et al.
International Journal of Cancer|January 15, 1986
Induction of cytotoxicity by interleukin-2 in T gamma-lymphoproliferative disordersP Allavena, M Introna, A Rambaldi, et al.
European Journal of Gynaecological Oncology|January 1, 1988
The role of cytoreduction in ovarian cancerF Zanaboni, A P Heintz, J B Trimbos, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|November 1, 1990
The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapyG Bolis, F Zanaboni, P Vanoli, et al.
Gynecologic Oncology|November 1, 1988
EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)G Bolis, C Bonazzi, F Landoni, et al.
Minerva Ginecologica|January 1, 1993
[Endometrial adenocarcinoma during the fertile age]M Franchi, P Tenti, F Ghezzi, et al.
Gynecologic Oncology|February 24, 2000
Clinical value of intraoperative gross examination in endometrial cancerM Franchi, F Ghezzi, M Melpignano, et al.
Journal of the National Cancer Institute|October 1, 1986
Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumorsP Allavena, F Zanaboni, S Rossini, et al.
The International Journal of Biological Markers|May 1, 1987
The biological tumor markers' myopia: a model with CA 125 and second-look in ovarian cancerF Zanaboni, G Accinelli, P Colombo, et al.
The International Journal of Biological Markers|January 1, 1991
Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEAF Boccardo, E Bombardieri, S Zanardi, et al.
Gynecologic Oncology|June 1, 1996
Octreotide in the management of bowel obstruction in terminal ovarian cancerG Mangili, M Franchi, A Mariani, et al.
International Journal of Cancer|January 15, 1986
Induction of cytotoxicity by interleukin-2 in T gamma-lymphoproliferative disordersP Allavena, M Introna, A Rambaldi, et al.
European Journal of Gynaecological Oncology|January 1, 1988
The role of cytoreduction in ovarian cancerF Zanaboni, A P Heintz, J B Trimbos, et al.
Pageof 5